Breaking New Ground: Restoring Fertility in Male Cancer Survivors

IVF.net NewsDesk

08 April 2025

| | | |

Advancements in medical research have opened new avenues for addressing infertility in male survivors of childhood cancer. A groundbreaking case involves Jaiwen Hsu, who, at the age of 11, was diagnosed with osteosarcoma—a type of bone cancer. The chemotherapy regimen necessary to treat his cancer posed a significant risk to his future fertility. In response, doctors at the University of Pittsburgh Medical Center (UPMC) harvested and cryopreserved a sample of his testicular tissue, containing sperm-forming stem cells, before he commenced treatment.

At 26, Hsu underwent a pioneering procedure where his preserved spermatogonial stem cells were reintroduced into his testes. This approach aims to regenerate spermatogenesis—the process of sperm production. While this technique has demonstrated success in animal models, including mice and monkeys, it remains experimental in humans. Early indications suggest that the transplanted tissue remains unharmed, though detectable sperm production has yet to be observed.

The implications of this procedure are particularly significant for prepubescent boys undergoing treatments that may compromise fertility. Unlike post-pubertal males, who have the option of sperm banking, younger patients lack mature sperm for preservation. Testicular tissue cryopreservation offers a potential solution by storing tissue that contains immature sperm cells, which could later be matured or reimplanted to restore fertility.

However, several challenges accompany this innovative approach. Ensuring the long-term viability and safety of cryopreserved testicular tissue is paramount. Risks include potential contamination with malignant cells, which could lead to cancer recurrence upon reimplantation. Additionally, the efficiency of spermatogenesis restoration and the overall success rates of such procedures in humans remain under investigation.

Ethical considerations also play a crucial role in the application of this technology. The experimental nature of testicular tissue transplantation raises questions about consent, particularly when procedures are performed on minors. Furthermore, the accessibility and cost of such treatments may limit their availability, potentially leading to disparities in care.

Despite these challenges, the progress in spermatogonial stem cell transplantation represents a promising frontier in oncofertility—a field dedicated to preserving reproductive health in cancer patients. Ongoing research and clinical trials are essential to refine these techniques, address safety concerns, and establish standardized protocols. As the medical community continues to explore these innovations, there is hope that fertility preservation will become an integral component of comprehensive cancer care for young patients.

Sources:

26 March 2025. medRxiv